344
Views
56
CrossRef citations to date
0
Altmetric
Brief Review

Cardiac pacemaker /f current and its inhibition by heart rate-reducing agents

Pages 1115-1122 | Accepted 15 Jun 2005, Published online: 15 Jun 2005
 

ABSTRACT

The ‘funny’ (/f) current, first described by Brown et al. in 1979 in pacemaker myocytes, is an inward current that slowly activates on hyperpolarization to the diastolic range of voltages. Extensive work has amply demonstrated its involvement in the generation of spontaneous activity. The extent of current activation determines the slope of diastolic depolarization and hence of pacemaker rate. Since /f is under cyclic adenosine monophosphate (cAMP)-mediated control by β-adrenergic and muscarinic stimulation, this mechanism underlies neurotransmitter modulation of cardiac rate and is therefore of fundamental physiological relevance. Their key role in pacemaking makes f‐channels a natural target for drugs aiming at regulation of pacemaker activity and cardiac rate. Both in the past and more recently, rate-reducing drugs that slow pacemaker activity by decreasing the rate of diastolic depolarization have been developed. These drugs act as specific f‐channel inhibitors. One of the latest such molecules developed, ivabradine, has a highly specific inhibitory action on f‐channels, which atypically depends on the current flow across the channel. These specific properties make the /f inhibition by ivabradine ‘use-dependent,’ a therapeutically beneficial property. Investigation of the interaction between rate-reducing molecules and specific regions of hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels, the molecular components of native f‐channels, will provide new strategies for more specific and efficient drug design. This short review addresses the major basic properties of cardiac f‐channels, with a focus on the mode of action of f‐channel inhibitors and on its possible molecular interpretation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.